Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990040 · ClinicalTrials.gov registry record
Registry for Participants With Short Bowel Syndrome
A clinical trial of Short Bowel Syndrome, sponsored by Shire.
- Active
- Registry status
- 1,806
- Enrollment target
- 1
- Study location
NCT01990040: Active study of Short Bowel Syndrome, sponsored by Shire.
NCT01990040 is a study of Short Bowel Syndrome that is active but no longer recruiting, run by Shire. The registered enrollment target is 1,806 participants, above the 79-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (2186% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01990040, a study of Short Bowel Syndrome, is active but no longer recruiting, sponsored by Shire.
- ACTIVE NOT RECRUITING
- Registry status
- 1,806 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
Primary Outcome
Incidence rates of colorectal cancer in participants will be calculated by dividing the number of incident colorectal cancer cases by the total number of person-years observed since beginning treatment with teduglutide.
Conditions Studied
Study Locations (1)
Massachusetts
- Shire - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,806 participants |
| Start Date | 2014-06-23 |
| Est. Completion | 2032-06-30 |
What the registry record for NCT01990040 still lists
NCT01990040 is an observational study that tracks outcomes without assigning an intervention. Its 1,806 participants enrollment target places it among the larger protocols in the corpus, above the 79-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (2186% higher).
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01990040 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01990040 about?
NCT01990040 is a clinical study titled "Registry for Participants With Short Bowel Syndrome". This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants...
What is the current status of trial NCT01990040?
This trial is currently active not recruiting. The enrollment target is 1,806 participants. The study started on 2014-06-23. Estimated completion is 2032-06-30.
What conditions does trial NCT01990040 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
Who is sponsoring clinical trial NCT01990040?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01990040 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01990040's enrollment target sits among peer trials
1,806 1st of 17 higher than 17 of 17 other Short Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Short Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
RECRUITING · NA
-
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
RECRUITING · Early Phase 1
-
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
RECRUITING · Phase 2
-
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
RECRUITING · NA
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI